Login / Signup

Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?

Luis Carlos SaizLeire LeacheMarta Gutiérrez-ValenciaJuan Erviti
Published in: British journal of haematology (2022)
Keyphrases
  • cell therapy
  • stem cells
  • healthcare
  • mesenchymal stem cells
  • palliative care
  • diffuse large b cell lymphoma
  • quality improvement
  • pain management
  • affordable care act
  • binding protein
  • health insurance